New drug cocktail shows promise for rare sarcomas
NCT ID NCT04200443
First seen Jan 05, 2026 · Last updated Jun 22, 2026 · Updated 25 times
Summary
This phase II trial tests whether combining cabozantinib (a targeted therapy) with temozolomide (a chemotherapy drug) can slow tumor growth in people with advanced leiomyosarcoma or other soft tissue sarcomas that cannot be surgically removed or have spread. About 96 participants will receive both drugs orally. The main goal is to see how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III UTERINE CORPUS LEIOMYOSARCOMA AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabozantinib and temozolomide
What this could lead to
If successful, this combination could offer a new treatment option to slow or stop tumor growth in people with advanced soft tissue sarcomas.
What could go wrong
This is a mid-stage trial with only 96 participants. The drugs may not work better than existing treatments and can cause side effects like fatigue, nausea, or liver issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.